Who are Bryostatin for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ethyl alcohol, Systemic Chemotherapy, Cyclophosphamide and azathioprine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bryostatin-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bryostatin for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bryostatin for Injection (Bryostatin for Injection) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytotoxic agent. Area: Oncology.

phase 2 Cytotoxic agent Protein kinase C (PKC) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bryostatin for Injection (Bryostatin for Injection) — Blanchette Rockefeller Neurosciences Insitute. Activates protein kinase C (PKC)

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bryostatin for Injection TARGET	Bryostatin for Injection	Blanchette Rockefeller Neurosciences Insitute	phase 2	Cytotoxic agent	Protein kinase C (PKC)
Ethyl alcohol	Ethyl alcohol	South Egypt Cancer Institute	marketed	Cytotoxic agent / Sclerosing agent
Systemic Chemotherapy	Systemic Chemotherapy	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Cytotoxic agent
Cyclophosphamide and azathioprine	Cyclophosphamide and azathioprine	Assistance Publique - Hôpitaux de Paris	phase 3	Immunosuppressive agents / Cytotoxic agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytotoxic agent class)

Blanchette Rockefeller Neurosciences Insitute · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bryostatin for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bryostatin-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing